Heartland

Delic Looks to Build a Sprawling ‘Psychedelic Ecosystem’

There have been a number of high profile initial public offerings in the psychedelic space, including COMPASS Pathways’ (NASDAQ: CMPS) $2 billion debut. While there are now more than 30 publicly traded companies in the space, there are thousands more private companies at various stages of funding and development. Delic Corp. (CSE: DELC) (OTCQB: DELCF) […]

The post Delic Looks to Build a Sprawling ‘Psychedelic Ecosystem’ appeared first on CannabisFN.

Published

1 month ago

January 20, 2021

Republished by Plato

Ryan Allway

January 20th, 2021

App, Exclusive, Psychedelics, Top Story

Delic Corp. (CSE: DELC) (OTCQB: DELCF) was founded by former High Times executives to cultivate these companies through a combination of awareness and capital. With three existing platforms reaching over 300,000 people per month, the company is already making inroads and educating the public while planning a flagship in-person event for 2021.

Click here to receive an investor presentation and corporate updates

Massive & Growing Market

Psychedelics have captured the attention of researchers after a series of promising early-stage clinical trials. In fact, the FDA has already approved ketamine nasal spray as a treatment for suicidal behavior and granted Breakthrough Therapy status to at least two psilocybin-based treatments for mental health disorders, like treatment-resistant depression.

Psychedelic Keyword Trends for ‘psilocybin’ – Source: Google Trends

Of course, the therapeutic potential for psychedelics is just scratching the surface of a larger revolution among consumers. More than 30 million American adults have tried psychedelics at least once in their life and psychedelic substances could be transformative for everything from enhancing creativity to dealing with past traumas in counseling sessions.

A Unique Business Model

Delic’s team is front and center in the psychedelic space, which enables them to see the best deals. Co-Founders Jackee and Matt Stang were executives at High Times before shifting their focus to psychedelics. In addition, the company’s board of directors includes names like Paul Rosen, Kraig Fox, Martin Tobias and Sashko Despotovski.

Recently, the company announced that Shep Gordon would join its advisory board. Mr. Gordon is an American talent manager, Hollywood film agent and producer that has advised countless businesses across different industries and will leverage his wealth of experience to help DELIC realize its ambitions in the psychedelics space.

Delic’s Executive Team – Source: Investor Presentation

It’s no secret that the psychedelics industry has attracted significant levels of capital as it targets a massive market opportunity. ATAI Life Sciences closed a $125 million Series C round, COMPASS Pathways raised $127.5 million in its going public transaction and MindMed Inc. raised C$80 million a recent bought deal—and these trends are poised to accelerate.

Click here to receive an investor presentation and corporate updates

Leveraging its high-profile team, media platform and capital, the company’s private equity model will focus on acquiring nimble, cash flowing and scalable psychedelic companies before they reach the masses through venture capital or a public listing. These dynamics provide shareholders with diversified access to some of the industry’s best opportunities.

More than a Media Empire

The psychedelics industry remains in the early stages of growth. Like the cannabis industry in 2006, the psychedelics industry presents investors with a unique opportunity to get involved at an early stage before it goes mainstream. Media companies could become key gatekeepers within the industry and have early access to relationships and dealflow.

Delic’s Reality Sandwich brand already reaches more than 300,000 people each month and is top ranked for high-profile Google keywords. In addition to an online presence, the company’s Meet Delic event will bring together mind-state technology vendors, industry experts and thought leaders to create one of the industry’s biggest events.

Moving forward, the company plans to make additional acquisitions in the psychedelics industry beyond media brands and events, leveraging its status as a publicly traded psychedelic wellness corporation. With a low float and DTC eligibility around the corner, the company should have ample access to capital to grow over the coming quarters.

Click here to receive an investor presentation and corporate updates

Looking Ahead

Delic Corp. (CSE: DELC) (OTCQB: DELCF) is uniquely positioned as a leading voice in the nascent psychedelics industry. With growing interest among investors, the company aims to leverage its presence to unlock value through private equity deals and build a sprawling psychedelic ecosystem.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Source: https://www.cannabisfn.com/delic-looks-to-build-a-sprawling-psychedelic-ecosystem/

Related Topics:brand business cannabis cbd development FDA growing growth heartland industry legal market producer

Up Next

Psychedelic Wellness-Focused Company Delic Corp Announces U. S. OTCQB Listing on OTC Markets & DTC Eligibility

Don't Miss

Show Us Your Grow Promo – £1000 Worth of Seeds and Merch to Be Won

Heartland

Charlotte’s Web’s CW Labs Announce New Scientific Collaboration Researching Hemp CBD Efficacy

Harvard Medical School’s Dr. Staci Gruber, Ph.D. is lead investigator BOULDER, Colo., Feb. 24, 2021 /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the market leader in hemp CBD wellness products, today announced a long-term scientific collaboration between McLean Hospital, a Harvard Medical School affiliate, and the Company. […]

Published

2 hours ago

February 26, 2021

Republished by Plato

Harvard Medical School’s Dr. Staci Gruber, Ph.D. is lead investigator

BOULDER, Colo., Feb. 24, 2021 /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the market leader in hemp CBD wellness products, today announced a long-term scientific collaboration between McLean Hospital, a Harvard Medical School affiliate, and the Company. Funding and product support are provided by the CW Labs division of Charlotte’s Web Inc.

Two distinct clinical trials will be overseen by lead researcher/investigator Dr. Staci A. Gruber, Ph. D, Associate Professor of Psychiatry at Harvard Medical School and Director of the MIND program at McLean Hospital in Belmont, Mass. These two studies will investigate the efficacy of a custom-formulated, hemp-derived high-CBD product. Clinical trial results are to be published in 2022. Dr. Gruber is also conducting a number of other studies, including a longitudinal observational study of Veterans who use a Charlotte’s Web product.

Dr. Gruber’s Marijuana Investigations for Neuroscientific Discovery (MIND) Program, established in 2014, is the first of its kind, and is dedicated to studying the long-term impact of cannabis and cannabinoids for medical and adult use which utilizes various clinical and cognitive tools as well as multimodal neuroimaging techniques.

We are honored to be working with Dr. Gruber, Harvard Medical School and McLean Hospital on these important clinical trials. Charlotte’s Web remains dedicated to supporting third-party research on hemp CBD investigated by some of the country’s top scientists.

Tim Orr, President of Charlotte’s Web’s CW Labs divison

For More Information About the MIND Program: https://www.drstacigruber.com/

About the MIND Program:

In 2014 Dr. Staci Gruber launched the Marijuana Investigations for Neuroscientific Discovery (MIND) program at Mclean Hospital, a Harvard Medical School affiliate. The MIND program is the first program of its kind designed to clarify the specific effects of medical cannabis use and is designed to support a wide range of study designs that generate ecologically valid, empirically sound data to close the gap between policy and science. MIND utilizes valid, robust research models and supports numerous projects designed to address the impact of medical cannabis on important variables such as cognition, brain structure and function, mood, conventional medication use, quality of life, pain, sleep, and other health-related measures. Through observational longitudinal investigations, survey studies, and clinical trials of custom-formulated cannabinoid products, MIND aims to examine the unique and synergistic effects of cannabis and its constituents to determine the efficacy of cannabinoids for specific conditions and diseases and to clarify the overall impact of cannabinoid-based treatments on physical and mental health. MIND is poised to improve patients’ overall wellbeing by striving to harness the therapeutic potential while minimizing harms of cannabinoid-based treatment.

About Charlotte’s Web and its CW Labs Division

Charlotte’s Web Labs (“CW Labs”) is the research and development division of Charlotte’s Web, advancing science around hemp-derived phytocannabinoids, terpenes and flavonoid compounds. CW Labs is headquartered at the Hauptmann Woodward Research Institute on the campus of the University at Buffalo’s Jacobs School of Medicine and The Center for Integrated Global Biomedical Sciences, and is part of the State University of New York (SUNY) network of 64 national and international research and medical institutions.

About Charlotte’s Web Holdings, Inc.

Charlotte’s Web Holdings, Inc., a Certified B Corporation headquartered in Boulder, Colorado, is the market leader in the production and distribution of innovative hemp-derived cannabidiol (“CBD”) wellness products under a family of brands which includes Charlotte’s Web™, CBD Medic™, CBD Clinic™, and Harmony Hemp. The Company’s premium quality products start with proprietary hemp genetics that are 100-percent American farm grown and manufactured into whole-plant hemp extracts containing a full spectrum of naturally occurring phytocannabinoids including CBD, CBC, CBG, terpenes, flavonoids and other beneficial hemp compounds. Charlotte’s Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, stress, inflammation recovery), CBD capsules,CBD topical creams and lotions, as well as CBD pet products for dogs. Charlotte’s Web is the number one CBD brand in the USA and distributed through more than 22,000 retail locations, select distributors and online through the Company’s website at www.CharlottesWeb.com.

Charlotte’s Web was founded by the Stanley Brothers with a mission to unleash the healing powers of botanicals through compassion and science, benefiting the planet and all who live upon it. Charlotte’s Web is a socially and environmentally conscious company and is committed to using business as a force for good and a catalyst for innovation. The Company weighs sound business decisions with consideration for how its efforts affect employees, customers, the environment, and diverse communities. The rate the Company pays for agricultural products reflects a fair and sustainable rate driving higher quality yield, encouraging regenerative farming practices, and supporting U.S. farming communities. Management believes that its socially oriented and environmentally responsible actions have a positive impact on its customers, suppliers, employees, and stakeholders. Charlotte’s Web donates a portion of its pre-tax earnings to charitable organizations.

Subscribe to Charlotte’s Web investor news.

Original press release

Published by NCV Newswire

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Source: https://www.newcannabisventures.com/charlottes-webs-cw-labs-announce-new-scientific-collaboration-researching-hemp-cbd-efficacy/

Heartland

Is cbd oil worth it’s price or should I stick to flower?

Published

3 hours ago

February 26, 2021

Republished by Plato

Tldr- bud or bottle?

So, I have been smoking high quality outdoor/greenhouse CBD/CBG from Beleafer. Now, my problem is, I dont really feel effects anymore, like, I use my cbd flower to mix with normal high potency weed and it works great, I feel less paranoia, thats all well, but as I say, if I smoke cbd alone its really like im doing something for nothing, this could be because I only get ounces from Beleafer as they last me months, but I probably have a tolerance with each strain by the time I finish it.

My issue is this. I need relief badly(psychological and physical issues), and when I used a high quality cbd oil, it helped, at low 5% dosage, but it was a pretty penny.

When I look at the cbd I want to get now its 129€ for 40% or I can get 2x 20% for the same price. They are 10ml bottles.

HOWEVER, I can get an ounce of indoor cbd for a similar slightly less price, only issue is shipping times, AND – IS SHIPPING OF CBD FLOWER STILL POSSIBLE OR TOTALLY STOPPED? This is probably my only issue now thinking about it.

I digress, basically I can get good strong cbd to smoke for months, or I can get a bottle of oil that could last a month depending if it works and if I stick to dosages instead of just start doing drops all day.

I enjoy cbd and it does work, I just dont know if I have a high tolerance now and it means I have to only fork out on high potency stuff.

Oh, the point of this post is that with smoking cbd, I cant say I feel any health benefits like pain relief etc, however when I used oil I think it definitely helped in more ways than just one (relaxed after a bong)

What would you do in this case? Bud or bottle?

Oh im in France so this makes it difficult with certain brands that dont ship intl.

Source: https://www.reddit.com/r/CBD/comments/lt0hvr/is_cbd_oil_worth_its_price_or_should_i_stick_to/